0002-3555 : Zepbound 8.33 mg/ml Subcutaneous Injection, Solution
| NDC: | 0002-3555 |
| Labeler: | Eli Lilly and Company |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Zepbound Kwikpen |
| Dosage Form: | Subcutaneous Injection, Solution |
| Application #: | NDA217806 |
| Rev. Date: |
NDC Package Codes:
- 0002-3555-11: 1 SYRINGE IN 1 CARTON (0002‑3555‑11) / 2.4 ML IN 1 SYRINGE (0002‑3555‑01)
Active Ingredients:
- Tirzepatide
Dosage Strength:
- 8.33 mg/mL
Pharmaceutical Classes:
- G-Protein-linked Receptor Interactions [MoA]
- GLP-1 Receptor Agonist [EPC]
- Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]
Related Products:
Based on records with the same trade name.- 0002-3511 Zepbound 25 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
- 0002-3522 Zepbound 20.8 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
- 0002-3533 Zepbound 16.7 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
- 0002-3544 Zepbound 12.5 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
- 0002-3566 Zepbound 4.17 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 0002-3544Next: 0002-3566 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.